目的 探讨新型冠状病毒感染后儿童多系统炎症综合征（multisystem inflammatory syndrome in children，MIS-C）患儿的临床特征及诊治策略。 方法 对徐州医科大学附属徐州儿童医院心血管内科2023年1—2月收治的4例MIS-C患儿的病例资料进行回顾性分析。 结果 4例患儿均伴有多脏器功能受累及炎症指标升高，入院后接受川崎病标准治疗方案效果不理想，其中2例予2次静脉注射免疫球蛋白冲击治疗，4例均加用糖皮质激素抗炎治疗，积极治疗后患儿预后良好。 结论 MIS-C常出现在新型冠状病毒感染后4~6周或更长时间，及时在川崎病标准治疗方案基础上加强抗炎治疗可取得良好治疗效果。
Abstract
Objective To investigate the clinical features and treatment strategies of multisystemic inflammatory syndrome in children (MIS-C) after severe acute respiratory syndrome coronavirus 2 infection. Methods A retrospective analysis was performed on the medical data of four children with MIS-C who were admitted to the Department of Cardiology, Xuzhou Children's Hospital, Xuzhou Medical University from January to February 2023. Results All four children had multiple organ involvements and elevated inflammatory markers, with a poor response to standard therapy for Kawasaki disease after admission. Two children were treated with intravenous immunoglobulin therapy pulse therapy twice, and all four children were treated with glucocorticoids. The children had a good prognosis after the treatment. Conclusions MIS-C often appears within 4-6 weeks or a longer time after severe acute respiratory syndrome coronavirus 2 infection, and anti-inflammatory therapy in addition to the standard treatment regimen for Kawasaki disease can help to achieve a favorable treatment outcome.
关键词
儿童多系统炎症综合征 /
新型冠状病毒 /
类川崎病 /
儿童
Key words
Multisystemic inflammatory syndrome in children /
Severe acute respiratory syndrome coronavirus 2 /
Kawasaki-like disease /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Brodsky NN, Ramaswamy A, Lucas CL. The mystery of MIS-C post-SARS-CoV-2 infection[J]. Trends Microbiol, 2020, 28(12): 956-958. PMID: 33190685. PMCID: PMC7556780. DOI: 10.1016/j.tim.2020.10.004.
2 Whittaker E, Bamford A, Kenny J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2[J]. JAMA, 2020, 324(3): 259-269. PMID: 32511692. PMCID: PMC7281356. DOI: 10.1001/jama.2020.10369.
3 Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic[J]. Lancet, 2020, 395(10239): 1741-1743. PMID: 32410759. PMCID: PMC7220168. DOI: 10.1016/S0140-6736(20)31129-6.
4 World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19[EB/OL]. (2020-05-15)[2023-02-15]. https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19.
5 Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic[J]. Lancet, 2020, 395(10237): 1607-1608. PMID: 32386565. PMCID: PMC7204765. DOI: 10.1016/S0140-6736(20)31094-1.
6 CDC Health Alert Network. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19)[EB/OL]. (2020-05-14)[2023-02-19]. https://emergency.cdc.gov/han/2020/han00432.asp.
7 Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents[J]. N Engl J Med, 2020, 383(4): 334-346. PMID: 32598831. PMCID: PMC7346765. DOI: 10.1056/NEJMoa2021680.
8 王亮, 沈永明. 类川崎病——儿童多系统炎症综合征诊疗相关研究现状[J]. 临床儿科杂志, 2021, 39(10): 792-796. DOI: 10.3969/j.issn.1000-3606.2021.10.019.
9 Nakra NA, Blumberg DA, Herrera-Guerra A, et al. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management[J]. Children (Basel), 2020, 7(7): 69. PMID: 32630212. PMCID: PMC7401880. DOI: 10.3390/children7070069.
10 Colmenero I, Santonja C, Alonso-Ria?o M, et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases[J]. Br J Dermatol, 2020, 183(4): 729-737. PMID: 32562567. PMCID: PMC7323219. DOI: 10.1111/bjd.19327.
11 Sharifkashani S, Bafrani MA, Khaboushan AS, et al. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: potential therapeutic targeting[J]. Eur J Pharmacol, 2020, 884: 173455. PMID: 32745604. PMCID: PMC7834210. DOI: 10.1016/j.ejphar.2020.173455.
12 蒋荣猛, 谢正德, 姜毅, 等. 儿童新型冠状病毒感染诊断、治疗和预防专家共识(第四版)[J]. 中华实用儿科临床杂志, 2022, 37(14): 1053-1065. DOI: 10.3760/cma.j.cn101070-20220610-00698.
13 王超, 秦虹, 张兴和, 等. 新型冠状病毒感染相关儿童多系统炎症综合征1例[J]. 中华临床感染病杂志, 2022, 15(5): 385-387. DOI: 10.3760/cma.j.issn.1674-2397.2022.05.010.
14 Fagherazzi G, Goetzinger C, Rashid MA, et al. Digital health strategies to fight COVID-19 worldwide: challenges, recommendations, and a call for papers[J]. J Med Internet Res, 2020, 22(6): e19284. PMID: 32501804. PMCID: PMC7298971. DOI: 10.2196/19284.
PDF(459 KB)
